GHK-Cu is often discussed as though one short name described one uniform experimental material and one established outcome. The source record is more specific. Some papers tested the copper complex, some tested copper-free GHK, some measured an endogenous peptide, and others embedded GHK in a delivery material. Those are different evidence objects.
This refreshed GHK-Cu research guide follows that distinction from molecular identity through experiment design. It summarizes what the cited studies directly measured, shows where evidence changes category, and defines the controls needed before a result from an isolated research reagent can be interpreted. It does not provide cosmetic, treatment, dosing, or personal-use instructions.
- GHK and GHK-Cu are related entities, but the copper-free tripeptide and its copper(II) complex are not interchangeable labels.
- The strongest direct GHK-Cu evidence in this source set comes from cell cultures and animal models, not controlled trials of an isolated research reagent.
- Collagen, glycosaminoglycan, MMP, oxidative-stress, and inflammatory findings were measured in different systems and should not be merged into one universal mechanism.
- Human-derived cells or ex-vivo follicles are human materials, but they are not clinical-outcome evidence.
- Identity, copper content, peptide purity, mass, matrix conditions, contamination controls, and matched comparators belong in the same study record.
- A product listing can describe a current research material; it cannot inherit efficacy from a cosmetic formulation, animal study, or endogenous pathway.
What Is GHK-Cu?
GHK is the three-amino-acid peptide glycyl-L-histidyl-L-lysine. Pickart and Thaler first described a tripeptide isolated from human plasma in 1973 after observing effects in a liver-cell system (PMID 4349963). That 1973 record is indexed without an abstract and reports no quantitative endpoint, so it fixes a discovery date rather than an effect size. GHK-Cu is the complex formed when GHK coordinates copper(II). The copper ion changes the chemical species under study; writing “GHK” and “GHK-Cu” as synonyms hides that experimental variable.
The name also does not define a complete material specification. A synthesized GHK-Cu reagent can vary in counterion, water content, residual solvents, peptide-related impurities, copper stoichiometry, aggregation, and concentration basis. Those attributes require lot-specific evidence. Endogenous occurrence, a PubMed record, or a blue color does not establish the identity or purity of a particular vial.
Registry identity of the two entities
| Attribute | GHK (copper-free tripeptide) | GHK-Cu (copper complex) |
|---|---|---|
| CAS number | 49557-75-7 | 89030-95-5 |
| Molecular formula | C14H24N6O4 | C14H24N6O4·Cu, a 1:1 copper(II) complex |
| Molecular weight | 340.38 g/mol | PubChem lists 402.92 g/mol for the deprotonated 1:1 cation; Apex’s catalog record separately states 403.93 g/mol as a summed peptide-plus-copper value, not a registry mass |
| Sequence | Gly-His-Lys, three residues | Gly-His-Lys with one Cu(II) in 1:1 coordination |
| PubChem CID | 73587 | 71587328 |
| Other names | glycyl-L-histidyl-L-lysine | copper tripeptide-1, prezatide copper |
| Category | What it identifies | What a study can support | What does not transfer automatically |
|---|---|---|---|
| GHK | The copper-free glycyl-L-histidyl-L-lysine tripeptide | Results for GHK in the stated model and matrix | Results for a copper complex or formulated product |
| GHK-Cu | A copper(II)-coordinated GHK complex | Results for the characterized complex under the stated conditions | Clinical, cosmetic, or product performance |
| GHK-containing formulation | A hydrogel, cream, carrier, or other defined material | Results for that complete formulation | Results for isolated GHK or GHK-Cu in another matrix |
GHK Versus GHK-Cu: Why Copper Coordination Matters
Copper coordination is not a decorative suffix. It can alter charge distribution, redox behavior, solubility, and interactions with proteins or assay components. It also creates an analytical question: did the experiment use free peptide, a preformed complex, peptide mixed with a copper salt, or an incompletely characterized preparation?
That distinction appears directly in the source record. Maquart and colleagues tested the tripeptide-copper complex in fibroblast collagen experiments, where stimulation began between 1 and 10 pM and peaked at 1 nM in vitro (PMID 3169264), while Choi and colleagues explicitly reported a copper-free GHK experiment in human keratinocytes and skin-equivalent models, describing higher proliferation, integrin expression, and p63-positive cell counts but no quantitative result (PMID 23019153). A review can discuss both under the broader GHK literature, but a method section and evidence table should preserve the chemical form.
From Plasma Tripeptide to Model-Specific Research
The 1973 plasma report established the historical starting point, not a modern clinical claim. Later work moved into connective-tissue models. GHK-Cu increased collagen synthesis in fibroblast culture (PMID 3169264) and produced a biphasic rise in sulfated glycosaminoglycan synthesis in normal human fibroblasts that was maximal at 1–10 nM (PMID 1522753). In rat subcutaneous wound chambers, repeated injections raised dry weight, DNA, protein, collagen, and glycosaminoglycan content concentration-dependently, with collagen stimulation about 2-fold that of non-collagen protein and no significant effect from the control tripeptide Glu-His-Pro (PMID 8227353).
The endogenous side of that history needs the same discipline. Choi and colleagues describe GHK as a naturally occurring copper(II)-chelating motif in human serum and cerebrospinal fluid (PMID 23019153), and that is where the sourced endogenous claim stops.
Those studies supplied mechanistic and preclinical hypotheses. They did not establish that any GHK-Cu material improves a human outcome. The material, species, injury model, concentration, vehicle, comparator, timing, and endpoint remain part of each claim.
What Mechanisms Have Actually Been Studied?
Extracellular-matrix readouts
Fibroblast work reported collagen and glycosaminoglycan changes after exposure to GHK-Cu (PMID 3169264; PMID 1522753). In rat wound chambers dosed at 2 mg per injection, MMP-9 expression persisted in treated tissue to day 22 and activated MMP-2 rose late, at days 18 to 22, while interstitial collagenase activity was unchanged (PMID 10383745). In dermal fibroblast culture, the complex raised MMP-2 alongside TIMP-1 and TIMP-2; copper ions alone reproduced that effect and copper-free GHK did not, although the abstract states no quantitative endpoint (PMID 11045606). The same 2 mg rat protocol increased chondroitin and dermatan sulfate and shifted the small proteoglycans, raising decorin mRNA and lowering biglycan mRNA, which peaked at day 12 (PMID 11121126).
These endpoints describe matrix regulation in particular systems. “More collagen” and “more MMP activity” are not universal quality scores; matrix deposition and turnover are coordinated processes, and the useful interpretation depends on model, timing, baseline state, and comparator.
Epidermal readouts sit in a separate lane. Copper-GHK increased proliferation in monolayer keratinocyte culture and raised PCNA, p63, and integrin alpha-6 and beta-1 expression in skin-equivalent models, with no quantitative outcome given in the abstract (PMID 19319546). A 2008 tissue-remodeling review collects these strands across models and, being a narrative synthesis rather than a single experiment, reports no quantitative finding of its own (PMID 18644225).
Redox and inflammatory models
An early in-vitro biochemical study found that copper-GHK blocked lipid peroxidation only when ferritin was the iron source, without significant superoxide-dismutase-like or ceruloplasmin-like activity, and reports no quantitative result for that inhibition (PMID 2244543). Much later, mouse work described lower reactive oxygen species, higher superoxide dismutase activity, and reduced TNF-alpha and IL-6 in lipopolysaccharide-induced acute lung injury, though that abstract also gives no quantitative endpoint (PMID 27517151). In bleomycin-induced pulmonary fibrosis, C57BL/6J mice challenged with 3 mg/kg bleomycin by tracheal instillation and assessed 21 days later received GHK-Cu intraperitoneally at 0.2, 2, or 20 µg/g/day on alternate days, with reduced inflammatory cytokines, lower myeloperoxidase activity, less collagen deposition, and a reversed MMP-9/TIMP-1 imbalance (PMID 31809714). These are model-specific biochemical and animal observations, not evidence that an isolated reagent treats lung disease.
GHK-Cu Evidence Lanes
| Evidence lane | Tested material and model | Direct observation | Boundary | Source |
|---|---|---|---|---|
| Cell culture | GHK-Cu, or copper-free GHK where stated, in fibroblast or keratinocyte systems | Collagen stimulation from 1–10 pM peaking at 1 nM; biphasic glycosaminoglycan synthesis maximal at 1–10 nM; MMP-2 with TIMP-1 and TIMP-2; integrin and p63 readouts reported separately for copper-GHK and for copper-free GHK | Does not establish a human cosmetic or clinical outcome | PMID 3169264, 1522753, 11045606, 19319546, 23019153 |
| Animal wound models | GHK-Cu injected into rat subcutaneous wound chambers | Collagen stimulation about 2-fold that of non-collagen protein; MMP-9 persisting to day 22; activated MMP-2 up at days 18–22; decorin mRNA up and biglycan mRNA down | Depends on species, injury model, vehicle, and endpoint | PMID 8227353, 10383745, 11121126 |
| Animal lung models | GHK-Cu in mouse injury or fibrosis models; bleomycin 3 mg/kg with GHK-Cu at 0.2, 2, or 20 µg/g/day | Reported oxidative-stress and inflammatory-pathway changes | Does not establish human treatment efficacy or safety | PMID 27517151, 31809714 |
| Human-derived ex vivo | AHK-Cu, an alanyl-histidyl-lysine copper analog, at 1 pM–1 nM in isolated human hair follicles | Follicle elongation measured outside the body; apoptosis reduction not statistically significant | Ex-vivo tissue is not a controlled human trial, and an analog is not GHK-Cu | PMID 17703734 |
| Engineered material | Cu-GHK-C16 peptide nanofibers in a hyaluronic-acid hydrogel crosslinked at 460–490 nm | Performance of a complete biomaterial system; the abstract reports no quantitative result for isolated GHK-Cu | Cannot be assigned to isolated GHK-Cu alone | PMID 37832839 |
For example, Pyo and colleagues reported follicle elongation and dermal-papilla-cell proliferation between 1 pM and 1 nM in human hair follicles held ex vivo, with a fall in apoptotic papilla cells that was not statistically significant (PMID 17703734). The complex actually dosed in that study was AHK-Cu, the alanyl-histidyl-lysine copper analog, so the finding names a neighbouring compound rather than this one, and human tissue origin does not make the experiment a clinical trial. Likewise, Lee and colleagues evaluated Cu-GHK-C16 nanofibers inside a hyaluronic-acid hydrogel photo-crosslinked under blue light at 460–490 nm, and the abstract reports no quantitative result for isolated GHK-Cu (PMID 37832839). That result belongs to the complete engineered material, not automatically to free GHK-Cu.
What Human Evidence Does This Guide Support?
The selected primary-source set contains human plasma history, human-derived cell and ex-vivo work, and reviews that discuss broader skin research. It does not provide a basis for claiming that an isolated Apex GHK-Cu research reagent produces a clinical or cosmetic outcome. A study can be “human-relevant” without being an intervention in living participants, and a formulated product can produce evidence that does not transfer to another formulation.
This boundary is especially important for search summaries and AI-generated answers. “Studied in human hair follicles” should not become “proven to grow hair,” and “reported collagen synthesis in fibroblasts” should not become “clinically proven to rebuild skin.” The first statements name the model and endpoint. The second statements silently change the evidence category.
GHK-Cu has a substantial mechanistic and preclinical literature, including cell-culture, animal-wound, and mouse-lung studies. Those findings do not establish the safety or effectiveness of an isolated research reagent in people, and results from copper-free GHK or a formulated GHK material should not be attributed to GHK-Cu without qualification.
Controls for a Defensible GHK-Cu Study
A study record should begin with the chemical form. Report whether the material is GHK, a preformed GHK-Cu complex, or peptide combined with a copper source during the experiment. Record sequence, terminal chemistry, counterion, lot, copper content or stoichiometric basis, concentration calculation, solvent or buffer, and any relevant equilibration step.
Analytical evidence should answer separate questions. Mass spectrometry can support molecular identity; a chromatographic method can estimate purity under its stated conditions; copper content may require an elemental method; and neither a mass match nor an HPLC area percentage establishes sterility, endotoxin status, concentration accuracy, or biological activity. The mass-spectrometry guide, HPLC purity guide, and COA-reading guide explain those boundaries.
Biological controls depend on the hypothesis. A useful design may need vehicle, untreated, copper-only, GHK-only, GHK-Cu, matrix-only, and positive controls, plus viability and contamination checks. The exact set should be prespecified from the model rather than copied from a different assay.
Research-Material Context
GHK-Cu holds no FDA, EMA, NMPA, MHRA, or other national regulatory approval anywhere in the world as a drug, and it has no approved therapeutic indication in any jurisdiction. Copper tripeptide-1 does appear as a cosmetic ingredient under separate ingredient frameworks; an ingredient listing is not a drug approval, and neither status transfers to a laboratory reagent.
Apex Laboratory lists GHK-Cu as a chemical reagent for laboratory research, specified as a lyophilized copper complex verified to ≥99% purity by HPLC and mass spectrometry and shipped against a per-lot certificate of analysis. That specification is a catalog claim about a supplied lot, not a study result: the lot COA is what settles it, and a purity percentage says nothing about copper stoichiometry, sterility, endotoxin, or activity. Current vial amount, availability, and fulfillment details belong on the live product record rather than in this evidence guide. That separation keeps scientific interpretation from drifting with catalog changes.
Current GHK-Cu research-reagent record
Review the live listing for current specifications and available documentation. The listing is for research use only and is not a cosmetic treatment, drug, or clinical formulation.
View the GHK-Cu research-reagent pageFor broader context, the tissue-repair research hub maps adjacent topics. The separate BPC-157 versus GHK-Cu comparison owns direct comparison intent; this guide remains focused on GHK/GHK-Cu identity, evidence, and study controls.
Frequently Asked Questions
What is GHK-Cu?
GHK-Cu is a copper(II)-coordinated complex of the tripeptide glycyl-L-histidyl-L-lysine. It should be distinguished from copper-free GHK and from formulated materials that contain GHK or GHK-Cu.
Are GHK and GHK-Cu the same?
No. GHK names the tripeptide, while GHK-Cu names a copper-coordinated complex. A study should state which chemical form was tested and how the material was prepared and characterized.
Does a blue color prove that a sample is pure GHK-Cu?
No. Color can be consistent with a copper complex, but it does not prove peptide sequence, copper stoichiometry, purity, concentration, sterility, endotoxin status, or biological activity.
What level of evidence exists for GHK-Cu?
The cited source set includes cell-culture, animal-wound, and mouse-lung studies, plus broader reviews. Those categories support mechanistic and preclinical interpretation, not a clinical or cosmetic claim for an isolated research reagent.
Can results from GHK or a GHK-containing formulation be assigned to GHK-Cu?
Not automatically. Copper-free GHK, GHK-Cu, and a complete formulation can differ chemically and experimentally. Any comparison must preserve the tested material, vehicle, model, concentration, and endpoint.
What controls matter in a GHK-Cu study?
Document the chemical form, sequence, terminal chemistry, copper basis, lot, identity and purity evidence, matrix, concentration calculation, contamination controls, comparators, viability checks, and prespecified endpoints.
References
- Pickart L, et al. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85-7. PMID: PMID 4349963.
- Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-6. PMID: PMID 3169264.
- Miller DM, et al. Effects of glycyl-histidyl-lysyl chelated Cu(II) on ferritin dependent lipid peroxidation. Adv Exp Med Biol. 1990;264:79-84. PMID: PMID 2244543.
- Wegrowski Y, et al. Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. Life Sci. 1992;51(13):1049-56. PMID: PMID 1522753.
- Maquart FX, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993;92(5):2368-76. PMID: PMID 8227353.
- Siméon A, et al. Expression and activation of matrix metalloproteinases in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. J Invest Dermatol. 1999;112(6):957-64. PMID: PMID 10383745.
- Siméon A, et al. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000;67(18):2257-65. PMID: PMID 11045606.
- Siméon A, et al. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol. 2000;115(6):962-8. PMID: PMID 11121126.
- Pyo HK, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-9. PMID: PMID 17703734.
- Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-88. PMID: PMID 18644225.
- Kang YA, et al. Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Arch Dermatol Res. 2009;301(4):301-6. PMID: PMID 19319546.
- Choi HR, et al. Stem cell recovering effect of copper-free GHK in skin. J Pept Sci. 2012;18(11):685-90. PMID: PMID 23019153.
- Park JR, et al. The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget. 2016;7(36):58405-58417. PMID: PMID 27517151.
- Ma WH, et al. Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways. Life Sci. 2020;241:117139. PMID: PMID 31809714.
- Lee S, et al. In situ photo-crosslinkable hyaluronic acid-based hydrogel embedded with GHK peptide nanofibers for bioactive wound healing. Acta Biomater. 2023;172:159-174. PMID: PMID 37832839.
